Progression with clinical features is associated with worse subsequent survival in multiple myeloma.

Adult Aged Aged, 80 and over Databases, Factual Disease Progression Disease-Free Survival Female Follow-Up Studies Humans Incidence Male Middle Aged Multiple Myeloma / diagnosis Recurrence Survival Rate

Journal

American journal of hematology
ISSN: 1096-8652
Titre abrégé: Am J Hematol
Pays: United States
ID NLM: 7610369

Informations de publication

Date de publication:
04 2019
Historique:
received: 13 10 2018
revised: 26 12 2018
accepted: 07 01 2019
pubmed: 22 1 2019
medline: 21 12 2019
entrez: 22 1 2019
Statut: ppublish

Résumé

Response rate and survival in multiple myeloma (MM) has improved in the era of proteasome inhibitors and immunomodulatory drugs. However, most patients eventually relapse with biochemical progression (BP) alone or with clinical features of end-organ damage (CP: clinical progression), without or without extramedullary (EM) disease. We conducted a retrospective cohort study of 252 patients with MM experiencing first relapse (time, T

Identifiants

DOI: 10.1002/ajh.25415 PMID: 30663805
pubmed: 30663805
doi: 10.1002/ajh.25415
doi:

Types de publication

Clinical Trial Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

439-445

Informations de copyright

© 2019 Wiley Periodicals, Inc.

Auteurs

Rajshekhar Chakraborty (R)

Taussig Cancer Center, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH.
ORCID: 0000-0001-7336-3003

Hien D Liu (HD)

Moffitt Cancer Center, Department of Blood and Marrow Transplant and Cellular Immunotherapy, Tampa, FL.

Lisa Rybicki (L)

Taussig Cancer Center, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH.

Jacqulyn Tomer (J)

Taussig Cancer Center, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH.

Jack Khouri (J)

Taussig Cancer Center, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH.

Robert M Dean (RM)

Taussig Cancer Center, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH.

Beth M Faiman (BM)

Taussig Cancer Center, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH.

Matt Kalaycio (M)

Taussig Cancer Center, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH.

Christy J Samaras (CJ)

Taussig Cancer Center, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH.

Navneet S Majhail (NS)

Taussig Cancer Center, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH.

Jason Valent (J)

Taussig Cancer Center, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Progression with clinical features is...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Progression with clinical features is...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Sujet âgé de 80 ans ou plus › Progression with clinical features is...
questionsmedicales.fr › Sciences de l'information › Mémorisation et recherche des informations › Bases de données comme sujet › Bases de données factuelles › Progression with clinical features is...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Évolution de la maladie › Progression with clinical features is...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Analyse de survie › Survie sans rechute › Progression with clinical features is...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études de suivi › Progression with clinical features is...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Progression with clinical features is...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Registre civil › Morbidité › Incidence › Progression with clinical features is...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Progression with clinical features is...
questionsmedicales.fr › Maladies du système immunitaire › Syndromes immunoprolifératifs › Paraprotéinémies › Myélome multiple › Progression with clinical features is...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Récidive › Progression with clinical features is...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Registre civil › Mortalité › Taux de survie › Progression with clinical features is...